

BAB VII

DAFTAR PUSTAKA

1. Sabia S, Elbaz A, Dugravot A, Head J, Shipley M, Hagger-Johnson G, et al. Impact of smoking on cognitive decline in early old age: The Whitehall II cohort study. *Arch Gen Psychiatry*. 2012;69:627–35.
2. Eknayan G, Lameire N, Eckardt K-U, Kasiske BL, Wheeler DC. Evaluation and management of chronic kidney disease. *Int Soc Nephrol*. 2013;3:5–32.
3. Prevention C for DC and. 2019 CKD fact sheet [Internet]. 2019 [cited 2019 Sep 25]. p. 1–6. Available from: <https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>
4. Kementrian Kesehatan Republik Indonesia. Hasil utama Riskesdas 2018. Balitbangkes. Jakarta; 2018.
5. Kazancioğlu R. Risk factors for chronic kidney disease: An update. *Kidney Int Suppl*. 2013;3:368–71.
6. Darsie B, Shlipak MG, Sarnak MJ, Katz R, Fitzpatrick AL, Odden MC. Kidney function and cognitive health in older adults: The cardiovascular health study. *Am J Epidemiol*. 2014;180:68–75.
7. Kurella-Tamura M, Wadley V, Yaffe K, A.McClure L, Howard G. Kidney function and cognitive impairment in US adults: The REGARDS (reasons for geographic and racial difference in stroke) study. *Natl Inst Heal*. 2009;1:1–7.
8. Foster R, Walker S, Brar R, Hiebert B, Komenda P, Rigatto C, et al. Cognitive impairment in advanced chronic kidney disease: the canadian frailty observation and interventions trial. *Am J Nephrol*. 2016;44:473–80.
9. Supriyadi, Wagiyo, Widowati S. Tingkat kualitas hidup pasien gagal ginjal kronik terapi hemodialisis. *J Kesehat Masy*. 2011;6:107–12.
10. Webster AC, Nagler E V., Morton RL, Masson P. Chronic kidney disease. *Lancet*. 2017;389:1238–52.
11. Jefferson JA, Shankiad SJ. The pathogenesis of focal segmental glomerulosclerosis. *Natl Inst Heal*. 2014;23:1–7.
12. Matovinović MS. Pathophysiology and classification of kidney disease. *J Int Fed Clin Chem Lab Med*. 2009;20:2–11.
13. Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. *J Natl Med Assoc*. 2002;94:7–13.
14. NICE Clinical guideline. Chronic kidney disease in adults : assessment and management. *Natl Inst Heal Care Excell*. 2019;1:17–30.
15. Coresh J, Astor BC, Greene T, Eknayan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis*. 2003;41:1–12.
16. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. *Prim Care - Clin Off Pract*. 2008;35:329–44.

17. Thimmaiah R, Murthy KK, Pinto D. Cognitive dysfunction in patients with renal failure requiring hemodialysis. *Indian J Psychol Med.* 2012;34:237–41.
18. Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: The neglected kidney-brain axis. *J Am Soc Nephrol.* 2013;24:353–63.
19. Mogi M, Horiuchi M. Clinical interaction between brain and kidney in small vessel disease. *Cardiol Res Pract.* 2011;1:1–4.
20. Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, et al. Cystatin C as a marker of cognitive function in elders: Findings from the Health ABC Study. *Ann Neurol.* 2008;63:798–802.
21. Vadakedath S, Kandi V. Dialysis : a review of the mechanism underlying complications in the management of chronic renal failure. *Cureus.* 2017;9:1–7.
22. Hall JE, Do Carmo JM, Da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. *Circ Res.* 2015;116:991–1006.
23. Hall JE. The kidney, hypertension, and obesity. *J Am Heart Assoc.* 2003;41:625–33.
24. Foëx P, Sear JW. Hypertension: pathophysiology and treatment. *Br J Anaesth.* 2004;4:71–5.
25. Esch JHM Van, Roks AJM, Danser AHJ. Hypertension and RAAS. *J Am Heart Assoc.* 2015;1:960–75.
26. Know the fact about highblood pressure [Internet]. National Center for Chronic Disease Prevention and Health Promotion. 2014. p. 2. Available from: https://www.cdc.gov/bloodpressure/docs/ConsumerEd_HBP.pdf
27. Soenarta AA, Erwinanto, Mumpuni ASS, Barack R, Lukito AA. Pedoman tatalaksana hipertensi pada penyakit kardiovaskular. *Perhimpun Dr Spes Kardiovask Indones.* 2015;1:2–15.
28. Shin H-R, Junsuk Kim W. Complication prevention for patients with hypertension. *World Heal Organ.* 2017;1:2–32.
29. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. *Oman Med J.* 2012;27:269–73.
30. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract.* 2018;138:271–81.
31. American diabetes association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2019. *Diabetes Care.* 2019;42:13–28.
32. Soelistijo S adi, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A. Pengelolaan diabete melitus tipe 2. In: *Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Diindonesia 2015.* 1st ed. Jakarta: Pengurus Besar Perkumpulan Endokrinologi Indonesia; 2015. p. 11–4.
33. Fujioka K. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. *J Am Acad Physician Assist.* 2007;1:3–8.

34. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? *Diabetes journals*. 2010;59:1117–25.
35. Fatimah RN. Diabetes melitus tipe 2. *Indones J Pharm*. 2016;27:74–9.
36. Ryan H, Trosciar A, Gfroerer J. Adult current smoking: Differences in definitions and prevalence estimates - NHIS and NSDUH, 2008. *J Environ Public Health*. 2012;1:1–9.
37. Negara S. Keputusan Menteri Kesehatan Republik Indonesia Nomor 1022/MENKES/SK/XI/2008 tentang pedoman pengendalian penyakit paru obstruktif kronik. 2008 p. 12–3.
38. US department of health and human services. Executive summary (the health consequences of smoking-50 years of progress: a report of the surgeon general). Vol. 1, Centers for Disease Control and Prevention. Atlanta; 2014.
39. Öberg M, Jaakkola MS, Woodward A, Peruga A, Prüss-Ustün A. Worldwide burden of disease from exposure to second-hand smoke: A retrospective analysis of data from 192 countries. *Lancet*. 2011;377:139–46.
40. Arsana PM, Rosandi R, Manaf A, Budhiarta A, Permana H, Sucipta KW, et al. Kajian teoritis dan epidemiologi. In: Panduan pengelolaan dislipidemia di Indonesia. Jakarta: Pengurus Besar Perkumpulan Endokrinologi Indonesia; 2015. p. 4–7.
41. Eaton CB, Feldman HA, Assaf AR, Mcphilips JB. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. *J Fam Pract*. 1993;38:17–22.
42. Smith DG. Epidemiology of dyslipidemia and economic burden on the healthcare system abstract. *Am J Manag Care*. 2007;13:68–71.
43. Hendromartono, Tjokroprawiro A, Sutjahjo A, Pranoto A, Murtiwi S, S SA, et al. Dislipidemia. In: Tjokroprawira A, Setiawan PB, Santoso D, Soegiarto G, editors. Buku Ajar Ilmu Penyakit Dalam. 2nd ed. Surabaya: Airlangga university press; 2007. p. 93–106.
44. European Society of Cardiology. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2019;1:1–78.
45. National cholesterol education program. Understanding cholesterol levels. *Natl Inst Heal*. 2001;108:2–22.
46. Hegele RA. Plasma lipoproteins: Genetic influences and clinical implications. *Nat Rev Genet*. 2009;10:109–21.
47. Erwinanto, Anwar S, J Nugroho EP. Pedoman tatalaksana dislipidemia. *J Kardiol Indones*. 2013;1:5–19.
48. Singh P, Saxena R, Srinivas G, Pande G, Chattopadhyay A. Cholesterol biosynthesis and homeostasis in regulation of the cell cycle. *PLoS One*. 2013;8:1–10.
49. Keeling MJ, Census H, As- N, Agency S, Grenfell B, Keeling M, et al. Structural mechanism for statin inhibition of HMG-CoA reductase. *Sci Mag*. 2001;292:1160–5.

50. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. *Curr Opin Lipidol.* 2008;19:295–300.
51. Yen CLE, Stone SJ, Koliwad S, Harris C, Farese R V. DGAT enzymes and triacylglycerol biosynthesis. *J Lipid Res.* 2008;49:2283–301.
52. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. *J Biol Chem.* 1998;273:16710–4.
53. Building healthy lifestyle. Vascular protection dyslipidemia clinical guide. *Chinook Heal Reg.* 2006;1:5–9.
54. O'Regan C, Cronin H, Kenny RA. Mental health and cognitive function. *Irish Longitud Study Ageing.* 2011;1:157–202.
55. Rosebud Roberts DSK. Classification and epidemiology of MCI. *Clin Geriatr Med.* 2013;29:1–19.
56. Caroli A, Prestia A, Galluzzi S, Ferrari C, Van Der Flier WM, Ossenkoppele R, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. *Neurology.* 2015;84:508–15.
57. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *J Alzheimer's Assoc.* 2011;1:1–13.
58. Rambe AS, Fitri FI, Utara US. Correlation between the montreal cognitive assessment-indonesian version (Moca-INA) and the mini-mental state examination (MMSE) in elderly. *Maced J Med Sci.* 2017;5:915–9.
59. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S. The montreal cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* 2005;1:1–5.
60. Milani SA, Marsiske M, Cottler LB, Chen X, Striley CW. Optimal cutoffs for the Montreal Cognitive Assessment vary by race and ethnicity. *J Alzheimer's Assoc.* 2018;10:773–81.
61. Carroll LE. The stages of chronic kidney disease and the estimated glomerular filtration rate. *J Lancaster Gen Hosp.* 2006;1:64–9.
62. Albert MA, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. *Circulation.* 2019;140:596–646.
63. Amelia R, Nasrul E, Basyar M. Artikel penelitian hubungan derajat merokok berdasarkan indeks Brinkman dengan kadar hemoglobin. *J Kesehat Andalas.* 2016;5:619–24.
64. Taufik ES. Pengaruh hipertensi terhadap fungsi kognitif pada lanjut usia [skripsi]. Fakultas Kedokteran Universitas Diponegoro; 2014.
65. Indonesia R. UNDANG-UNDANG NEGARA REPUBLIK INDONESIA NOMOR 13 TAHUN 1998 TENTANG KESEJAHTERAAN LANJUT

- USIA. Jakarta: Sekretariat Negara; 1998 p. 1–24.
- 66. US Department of Health and Human Services. Treatment Methods for Kidney Failure : Hemodialysis. Natl Inst Diabetes Dig Kidney Dis. 2009;1:1–11.
 - 67. Weiner DE, Scott TM, Giang LM, Agganis BT, Sorensen EP, Tighiouart H, et al. Cardiovascular disease and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis. 2011;58:773–81.
 - 68. Nugroho BAW. Gula darah tidak terkontrol sebagai faktor risiko gangguan fungsi kognitif pada penderita diabetes melitus tipe 2 usia dewasa menengah. Universitas Udayana; 2015.
 - 69. Harada CN, Natelson Love MC, Triebel K. Normal Cognitive Aging. Public Access. Clin Geriatr Med. 2013;29:737–52.
 - 70. Al Rasyid I, Syafrita Y, Sastri S. Hubungan Faktor Risiko dengan Fungsi Kognitif pada Lanjut Usia Kecamatan Padang Panjang Timur Kota Padang Panjang. J Kesehat Andalas. 2017;6:49.
 - 71. Vos PF, Zilch O, Jennekens-Schinkel A, Salden M, Nuyen J, Kooistra M MP, et al. Effect of short daily home haemodialysis on quality of life, cognitive functioning and the electroencephalogram. Nephrol Dial Transplant. 2006;21:2529–35.
 - 72. Nugroho IA, Asti AD, Kuatno L. Hubungan Tingkat Pendidikan Dan Aktifitas Fisik Terhadap Fungsi Kognitif Lansia Usia 60 Tahun Di Wilayah Kerja Puskesmas Gombong Ii Kabupaten Kebumen. J Ilm Kesehat Keperawatan. 2017;13:146–50.
 - 73. Murray AM, Tupper DE, Knopman DS. Cognitive impairment in hemodialysis patients is common. Am Acad Neurol. 2012;1:217–22.